168 related articles for article (PubMed ID: 35441424)
21. Tyrosine kinase inhibitors in chronic myeloid leukaemia and emergent cardiovascular disease.
Leong D; Aghel N; Hillis C; Siegal D; Karampatos S; Rangarajan S; Pond G; Seow H
Heart; 2021 Apr; 107(8):667-673. PubMed ID: 33419879
[TBL] [Abstract][Full Text] [Related]
22. Real-world analysis of tyrosine kinase inhibitor treatment patterns among patients with chronic myeloid leukemia in the United States.
Henk HJ; Woloj M; Shapiro M; Whiteley J
Clin Ther; 2015 Jan; 37(1):124-33. PubMed ID: 25467191
[TBL] [Abstract][Full Text] [Related]
23. [Prevalence of Adverse Effects of Tyrosine Kinase Inhibitors Used in Management of Chronic Myeloid Leukemia at Sidi Bel-Abbès University Hospital Center].
Matmour D; Si-Ali N; Benmehimda NC; Beloufa S; Belfrak F; Mahi E; Merad Y; Toumi H; Benlazar M
Ann Pharm Fr; 2022 Nov; 80(6):932-942. PubMed ID: 35469781
[TBL] [Abstract][Full Text] [Related]
24. Four-year follow-up of patients with imatinib-resistant or intolerant chronic myeloid leukemia receiving dasatinib: efficacy and safety.
Huang X; Jiang Q; Hu J; Li J; Jin J; Meng F; Shen Z; Liu T; Wu D; Wang J; Wang J
Front Med; 2019 Jun; 13(3):344-353. PubMed ID: 30159669
[TBL] [Abstract][Full Text] [Related]
25. Patterns of surveillance for late effects of BCR-ABL tyrosine kinase inhibitors in survivors of pediatric Philadelphia chromosome positive leukemias.
Smith SM; Sabnis HS; Lewis RW; Effinger KE; Bergsagel J; Patterson B; Mertens A; Sakamoto KM; Schapira L; Castellino SM
BMC Cancer; 2021 Apr; 21(1):474. PubMed ID: 33926411
[TBL] [Abstract][Full Text] [Related]
26. Tyrosine Kinase Inhibitors Early in the Disease Course: Lessons From Chronic Myelogenous Leukemia.
Yilmaz M; Jabbour E
Semin Oncol; 2015 Dec; 42(6):876-86. PubMed ID: 26615132
[TBL] [Abstract][Full Text] [Related]
27. Four-Dimensional Echocardiographic Evaluation of Left Ventricular Systolic Functions in Patients with Chronic Myeloid Leukaemia Receiving Tyrosine Kinase Inhibitors.
Karakulak UN; Aladag E; Hekimsoy V; Sahiner ML; Kaya EB; Ozer N; Aksu S; Demiroglu H; Goker H; Buyukasik Y; Ozcebe O; Sayinalp N; Haznedaroglu IC
Cardiovasc Toxicol; 2021 Mar; 21(3):216-223. PubMed ID: 33068232
[TBL] [Abstract][Full Text] [Related]
28. Excellent therapeutic results achieved in chronic myeloid leukemia patients with front-line imatinib and early treatment modifications in suboptimal responders: a retrospective study on 91 unselected patients.
Cerrano M; Crisà E; Pregno P; Aguzzi C; Riccomagno P; Boccadoro M; Ferrero D
Am J Hematol; 2013 Oct; 88(10):838-42. PubMed ID: 23757199
[TBL] [Abstract][Full Text] [Related]
29. Cross-Intolerance With Dasatinib Among Imatinib-Intolerant Patients With Chronic Phase Chronic Myeloid Leukemia.
Khoury HJ; Goldberg SL; Mauro MJ; Stone RM; Deininger MW; Bradley-Garelik MB; Mohamed H; Guilhot F
Clin Lymphoma Myeloma Leuk; 2016 Jun; 16(6):341-349.e1. PubMed ID: 27133948
[TBL] [Abstract][Full Text] [Related]
30. Off-target effects of BCR-ABL1 inhibitors and their potential long-term implications in patients with chronic myeloid leukemia.
Steegmann JL; Cervantes F; le Coutre P; Porkka K; Saglio G
Leuk Lymphoma; 2012 Dec; 53(12):2351-61. PubMed ID: 22616642
[TBL] [Abstract][Full Text] [Related]
31. Dasatinib in imatinib-resistant or imatinib-intolerant chronic myeloid leukemia in blast phase after 2 years of follow-up in a phase 3 study: efficacy and tolerability of 140 milligrams once daily and 70 milligrams twice daily.
Saglio G; Hochhaus A; Goh YT; Masszi T; Pasquini R; Maloisel F; Erben P; Cortes J; Paquette R; Bradley-Garelik MB; Zhu C; Dombret H
Cancer; 2010 Aug; 116(16):3852-61. PubMed ID: 20564086
[TBL] [Abstract][Full Text] [Related]
32. Dasatinib induces complete hematologic and cytogenetic responses in patients with imatinib-resistant or -intolerant chronic myeloid leukemia in blast crisis.
Cortes J; Rousselot P; Kim DW; Ritchie E; Hamerschlak N; Coutre S; Hochhaus A; Guilhot F; Saglio G; Apperley J; Ottmann O; Shah N; Erben P; Branford S; Agarwal P; Gollerkeri A; Baccarani M
Blood; 2007 Apr; 109(8):3207-13. PubMed ID: 17185463
[TBL] [Abstract][Full Text] [Related]
33. Cardiovascular Toxicity in Cancer Patients Treated with Tyrosine Kinase Inhibitors: A Real-World Single-Center Experience.
Novo G; Di Lisi D; Bronte E; Macaione F; Accurso V; Badalamenti G; Rinaldi G; Siragusa S; Novo S; Russo A
Oncology; 2020; 98(7):445-451. PubMed ID: 32348984
[TBL] [Abstract][Full Text] [Related]
34. [Management of vascular adverse events during tyrosine kinase inhibitors in patients with chronic myeloid leukemia].
Takaku T
Rinsho Ketsueki; 2020; 61(9):1018-1027. PubMed ID: 33162495
[TBL] [Abstract][Full Text] [Related]
35. Evaluation of Long-Term Chronic Myeloid Leukemia Treatment Practices with Tyrosine Kinase Inhibitors in a National Cohort of Veterans.
Kreys ED; Frei CR; Villarreal SM; Bollinger MJ; Jones X; Koeller JM
Pharmacotherapy; 2017 Mar; 37(3):278-286. PubMed ID: 28052354
[TBL] [Abstract][Full Text] [Related]
36. Efficacy and safety of dasatinib in imatinib-resistant or -intolerant patients with chronic myeloid leukemia in blast phase.
Cortes J; Kim DW; Raffoux E; Martinelli G; Ritchie E; Roy L; Coutre S; Corm S; Hamerschlak N; Tang JL; Hochhaus A; Khoury HJ; Brümmendorf TH; Michallet M; Rege-Cambrin G; Gambacorti-Passerini C; Radich JP; Ernst T; Zhu C; Van Tornout JM; Talpaz M
Leukemia; 2008 Dec; 22(12):2176-83. PubMed ID: 18754032
[TBL] [Abstract][Full Text] [Related]
37. Cost-effectiveness analysis of second-line tyrosine kinase inhibitor treatment for chronic myelogenous leukemia.
Whalen J; Stillman I; Ambavane A; Felber E; Makenbaeva D; Bolinder B
J Med Econ; 2016; 19(5):445-61. PubMed ID: 26613118
[TBL] [Abstract][Full Text] [Related]
38. A retrospective study of the prescribing and outcomes of tyrosine kinase inhibitors in chronic myeloid leukaemia over a period of more than 10 years.
Lang AS; Mounier M; Roques M; Chretien ML; Boulin M
J Clin Pharm Ther; 2015 Aug; 40(4):391-7. PubMed ID: 25865674
[TBL] [Abstract][Full Text] [Related]
39. Analysis of cardiovascular and arteriothrombotic adverse events in chronic-phase CML patients after frontline TKIs.
Jain P; Kantarjian H; Boddu PC; Nogueras-González GM; Verstovsek S; Garcia-Manero G; Borthakur G; Sasaki K; Kadia TM; Sam P; Ahaneku H; O'Brien S; Estrov Z; Ravandi F; Jabbour E; Cortes JE
Blood Adv; 2019 Mar; 3(6):851-861. PubMed ID: 30885996
[TBL] [Abstract][Full Text] [Related]
40. Dasatinib rapidly induces deep molecular response in chronic-phase chronic myeloid leukemia patients who achieved major molecular response with detectable levels of BCR-ABL1 transcripts by imatinib therapy.
Shiseki M; Yoshida C; Takezako N; Ohwada A; Kumagai T; Nishiwaki K; Horikoshi A; Fukuda T; Takano H; Kouzai Y; Tanaka J; Morita S; Sakamoto J; Sakamaki H; Inokuchi K
Int J Clin Oncol; 2017 Oct; 22(5):972-979. PubMed ID: 28550414
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
